VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang
VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang operates in Diversified Metals & Mining.
VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang (VX1) - Total Liabilities
Latest total liabilities as of September 2024: €6.61 Billion EUR
Based on the latest financial reports, VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang (VX1) has total liabilities worth €6.61 Billion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang - Total Liabilities Trend (2016–2023)
This chart illustrates how VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang Competitors by Total Liabilities
The table below lists competitors of VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FenixOro Gold Corp
PINK:FDVXF
|
USA | $1.31 Million |
|
The Tinley Beverage Company Inc
OTCQB:TNYBF
|
USA | $1.20 Million |
|
Avillion Bhd
KLSE:8885
|
Malaysia | RM135.53 Million |
|
Resintech Bhd
KLSE:7232
|
Malaysia | RM119.78 Million |
|
Highfield Resources Ltd
AU:HFR
|
Australia | AU$72.71 Million |
|
FMR Resources Ltd
AU:FMR
|
Australia | AU$444.93K |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
USA | $13.28 Million |
|
Blue Moon Metals Inc
PINK:BMOOF
|
USA | $80.76K |
Liability Composition Analysis (2016–2023)
This chart breaks down VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang (2016–2023)
The table below shows the annual total liabilities of VERTEX PHARMACEUTIC - Dusseldorf Stock Exchang from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €5.15 Billion | +21.51% |
| 2022-12-31 | €4.24 Billion | +27.18% |
| 2021-12-31 | €3.33 Billion | +8.73% |
| 2020-12-31 | €3.06 Billion | +37.25% |
| 2019-12-31 | €2.23 Billion | +23.34% |
| 2018-12-31 | €1.81 Billion | +20.42% |
| 2017-12-31 | €1.50 Billion | -3.52% |
| 2016-12-31 | €1.56 Billion | -- |